ROCHE_WEB THUMBNAIL
April 16, 2024

Faricimab – The Fight Against Retinal Diseases

Faricimab (Vabysmo) is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease by…

popular posts
[Heidelberg] Website article thumbnail 01
April 9, 2025

Visualizing the Retinal Vasculature

Apr11_Article
April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

Article 1 Day 1_ ARVO
May 6, 2025

Inspiring Award Lectures at ARVO 2025 Highlight Decades of Visionary Work

Rear,View,Of,Group,Of,Diverse,Business,People,Listening,To
May 5, 2025

Translational Research at ARVO 2025: When Clinicians and Researchers Solve Problems Together

latest posts
Article 1 Day 1_ ARVO
May 6, 2025

Inspiring Award Lectures at ARVO 2025 Highlight Decades of Visionary Work

Web Day 1
May 5, 2025

ARVO 2025 Opens Amidst Darkening Political Climate for Scientific Research

Rear,View,Of,Group,Of,Diverse,Business,People,Listening,To
May 5, 2025

Translational Research at ARVO 2025: When Clinicians and Researchers Solve Problems Together

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Eylea HD for Macular Edema Following RVO
April 18, 2025

FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO 

unnamed (22)
April 16, 2025

FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis

Apr11_Article
April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

Thumbnail Article_Article 4 (1)
April 6, 2025

Eyeing the Future of AMD at APAO 2025

Discover our fascinating content at issuu

explore